Leveraging current capacity to address the high prevalence of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis in South Africa: Modelling potential costs and benefits of near point-of-care GeneXpert testing for STIs
- 1Health Economics and Epidemiology Research Office, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa;
- 2Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, United Kingdom; Health Economics and Epidemiology Research Office, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa;
- 3Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, USA; Department of Global Health, Amsterdam Institute for Global Health and Development, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
Abstract
South Africa has high sexually transmitted infections (STIs) prevalence and currently implements syndromic management, which has limitations including untreated asymptomatic infections and excess antibiotic use. Diagnostic tools like GeneXpert may offer potential improvements. We evaluated potential costs and benefits of GeneXpert for STIs testing. We developed a static analytical model using existing data over a one-year time horizon (January-December 2024) from a provider perspective. We estimated costs (2024 USD), outcomes, cost-effectiveness, and budget impact of syndromic management and multiple near point-of-care (i.e., off-site laboratory) GeneXpert testing scenarios for Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis. Target groups included symptomatic individuals, antenatal care (ANC) attendees, and HIV testers. Deterministic sensitivity analysis was conducted on key parameters. Cost per person, and per person correctly diagnosed and treated ranged from 21−29 under syndromic management and 88−755 in GeneXpert scenarios. Syndromic management cost the healthcare system an estimated $24.1 million per year; symptomatic GeneXpert testing would cost substantially more: 102.1−207.8 million, and $300.9 million-$2.1 billion for GeneXpert scenarios involving symptomatic individuals, ANC attendees, and HIV testers. GeneXpert testing reduces excess antibiotic use by up to 88% compared to syndromic management. Of scenarios modelled, three were on the cost-effectiveness frontier: syndromic management, S4: symptomatic adults and adolescent girls and young women HIV testers, and S8: symptomatic adults, ANC attendees and HIV testers. While syndromic management was least costly, incremental cost per additional person correctly diagnosed and treated was $863 (S4) and $1,064 (S8). These scenarios would cost $3.5 and $12.0 billion over 5-years, respectively, compared to $146.0 million in syndromic management. Staff and diagnostic cost were the most influential parameter in sensitivity analysis. Prioritizing GeneXpert testing for symptomatic individuals and high-risk groups (e.g., HIV testers) can improve STI management but requires additional investment. These findings support the need for targeted strategies to optimise STI control.
Related
- Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae among Ugandan Adolescents and Adults Vulnerable to HIV
- Prevalence of Neisseria gonorrhoeae, Ureaplasma urealyticum, and Chlamydia trachomatis infections in 37,680 patients in Guangzhou, China
- Mycoplasmal endosymbionts of Trichomonas vaginalis are associated with reduced risk for Chlamydia trachomatis endometrial infection in asymptomatic, coinfected, women.
- Pkn1 kinase is a critical regulator of cell division in Chlamydia trachomatis
- Chlamydia trachomatis Incidence in Relation to Vaginal Microbiota Dynamics, Immunogenetics and Exposures in a Cohort of Young Student Women in France
BibTeX
@article{lekodeba2026leveraging,
title = {{Leveraging current capacity to address the high prevalence of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis in South Africa: Modelling potential costs and benefits of near point-of-care GeneXpert testing for STIs}},
author = {Nkgomeleng Lekodeba and Katherine Snyman and Brooke E Nichols and Lise Jamieson},
journal = {PLOS Global Public Health},
year = {2026},
month = jul,
doi = {10.1371/journal.pgph.0004480},
url = {https://doi.org/10.1371/journal.pgph.0004480},
note = {CC BY},
}
RIS
TY - JOUR
TI - Leveraging current capacity to address the high prevalence of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis in South Africa: Modelling potential costs and benefits of near point-of-care GeneXpert testing for STIs
AU - Nkgomeleng Lekodeba
AU - Katherine Snyman
AU - Brooke E Nichols
AU - Lise Jamieson
PY - 2026
DA - 2026/07/24
JO - PLOS Global Public Health
DO - 10.1371/journal.pgph.0004480
UR - https://doi.org/10.1371/journal.pgph.0004480
AB - South Africa has high sexually transmitted infections (STIs) prevalence and currently implements syndromic management, which has limitations including untreated asymptomatic infections and excess antibiotic use. Diagnostic tools like GeneXpert may offer potential improvements. We evaluated potential costs and benefits of GeneXpert for STIs testing. We developed a static analytical model using existing data over a one-year time horizon (January-December 2024) from a provider perspective. We estimated costs (2024 USD), outcomes, cost-effectiveness, and budget impact of syndromic management and multiple near point-of-care (i.e., off-site laboratory) GeneXpert testing scenarios for Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis. Target groups included symptomatic individuals, antenatal care (ANC) attendees, and HIV testers. Deterministic sensitivity analysis was conducted on key parameters. Cost per person, and per person correctly diagnosed and treated ranged from 21−29 under syndromic management and 88−755 in GeneXpert scenarios. Syndromic management cost the healthcare system an estimated $24.1 million per year; symptomatic GeneXpert testing would cost substantially more: 102.1−207.8 million, and $300.9 million-$2.1 billion for GeneXpert scenarios involving symptomatic individuals, ANC attendees, and HIV testers. GeneXpert testing reduces excess antibiotic use by up to 88% compared to syndromic management. Of scenarios modelled, three were on the cost-effectiveness frontier: syndromic management, S4: symptomatic adults and adolescent girls and young women HIV testers, and S8: symptomatic adults, ANC attendees and HIV testers. While syndromic management was least costly, incremental cost per additional person correctly diagnosed and treated was $863 (S4) and $1,064 (S8). These scenarios would cost $3.5 and $12.0 billion over 5-years, respectively, compared to $146.0 million in syndromic management. Staff and diagnostic cost were the most influential parameter in sensitivity analysis. Prioritizing GeneXpert testing for symptomatic individuals and high-risk groups (e.g., HIV testers) can improve STI management but requires additional investment. These findings support the need for targeted strategies to optimise STI control.
SN - 2767-3375
ER -